Cargando…

Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis

This study aimed to determine whether autologous orthobiologic tissue source affects pain and functional outcomes in patients with symptomatic knee osteoarthritis (OA) who received microfragmented adipose tissue (MFAT) or bone marrow aspirate concentrate (BMAC) injection. We retrospectively reviewed...

Descripción completa

Detalles Bibliográficos
Autores principales: Mautner, Kenneth, Bowers, Robert, Easley, Kirk, Fausel, Zachary, Robinson, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811695/
https://www.ncbi.nlm.nih.gov/pubmed/31328447
http://dx.doi.org/10.1002/sctm.18-0285
_version_ 1783462520977096704
author Mautner, Kenneth
Bowers, Robert
Easley, Kirk
Fausel, Zachary
Robinson, Ryan
author_facet Mautner, Kenneth
Bowers, Robert
Easley, Kirk
Fausel, Zachary
Robinson, Ryan
author_sort Mautner, Kenneth
collection PubMed
description This study aimed to determine whether autologous orthobiologic tissue source affects pain and functional outcomes in patients with symptomatic knee osteoarthritis (OA) who received microfragmented adipose tissue (MFAT) or bone marrow aspirate concentrate (BMAC) injection. We retrospectively reviewed prospectively collected data from patients who received BMAC or MFAT injection for symptomatic knee OA. Patients completed baseline and follow‐up surveys. Each survey included the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, Emory Quality of Life (EQOL) questionnaire, and Visual Analog Scale (VAS) for pain. The follow‐up responses were compared with baseline for all patients and between BMAC and MFAT groups. A total of 110 patients met inclusion criteria, with 76 patients (BMAC 41, MFAT 35) and 106 knees (BMAC 58, MFAT 48) having appropriate follow‐up data. The BMAC group included 17 females and 24 males, with a mean age of 59 ± 11 years. The MFAT group included 23 females and 12 males, with a mean age of 63 ± 11 years. Minimum follow‐up time was 0.5 years. Mean follow‐up time was 1.80 ± 0.88 years for BMAC and 1.09 ± 0.49 years for MFAT. Both groups had significant improvement in EQOL, VAS, and all KOOS parameters preprocedure versus postprocedure (p < .001). There was not a significant difference when comparing postprocedure scores between groups (p = .09, .38, .63, .94, .17, .15, .70, respectively). These data demonstrate significant improvement in pain and function with both MFAT and BMAC injections in patients with symptomatic knee OA without a significant difference in improvement when comparing the two autologous tissue sources. stem cells translational medicine 2019;8:1149–1156
format Online
Article
Text
id pubmed-6811695
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-68116952019-10-30 Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis Mautner, Kenneth Bowers, Robert Easley, Kirk Fausel, Zachary Robinson, Ryan Stem Cells Transl Med Human Clinical Article This study aimed to determine whether autologous orthobiologic tissue source affects pain and functional outcomes in patients with symptomatic knee osteoarthritis (OA) who received microfragmented adipose tissue (MFAT) or bone marrow aspirate concentrate (BMAC) injection. We retrospectively reviewed prospectively collected data from patients who received BMAC or MFAT injection for symptomatic knee OA. Patients completed baseline and follow‐up surveys. Each survey included the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, Emory Quality of Life (EQOL) questionnaire, and Visual Analog Scale (VAS) for pain. The follow‐up responses were compared with baseline for all patients and between BMAC and MFAT groups. A total of 110 patients met inclusion criteria, with 76 patients (BMAC 41, MFAT 35) and 106 knees (BMAC 58, MFAT 48) having appropriate follow‐up data. The BMAC group included 17 females and 24 males, with a mean age of 59 ± 11 years. The MFAT group included 23 females and 12 males, with a mean age of 63 ± 11 years. Minimum follow‐up time was 0.5 years. Mean follow‐up time was 1.80 ± 0.88 years for BMAC and 1.09 ± 0.49 years for MFAT. Both groups had significant improvement in EQOL, VAS, and all KOOS parameters preprocedure versus postprocedure (p < .001). There was not a significant difference when comparing postprocedure scores between groups (p = .09, .38, .63, .94, .17, .15, .70, respectively). These data demonstrate significant improvement in pain and function with both MFAT and BMAC injections in patients with symptomatic knee OA without a significant difference in improvement when comparing the two autologous tissue sources. stem cells translational medicine 2019;8:1149–1156 John Wiley & Sons, Inc. 2019-07-21 /pmc/articles/PMC6811695/ /pubmed/31328447 http://dx.doi.org/10.1002/sctm.18-0285 Text en © 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Human Clinical Article
Mautner, Kenneth
Bowers, Robert
Easley, Kirk
Fausel, Zachary
Robinson, Ryan
Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title_full Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title_fullStr Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title_full_unstemmed Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title_short Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis
title_sort functional outcomes following microfragmented adipose tissue versus bone marrow aspirate concentrate injections for symptomatic knee osteoarthritis
topic Human Clinical Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811695/
https://www.ncbi.nlm.nih.gov/pubmed/31328447
http://dx.doi.org/10.1002/sctm.18-0285
work_keys_str_mv AT mautnerkenneth functionaloutcomesfollowingmicrofragmentedadiposetissueversusbonemarrowaspirateconcentrateinjectionsforsymptomatickneeosteoarthritis
AT bowersrobert functionaloutcomesfollowingmicrofragmentedadiposetissueversusbonemarrowaspirateconcentrateinjectionsforsymptomatickneeosteoarthritis
AT easleykirk functionaloutcomesfollowingmicrofragmentedadiposetissueversusbonemarrowaspirateconcentrateinjectionsforsymptomatickneeosteoarthritis
AT fauselzachary functionaloutcomesfollowingmicrofragmentedadiposetissueversusbonemarrowaspirateconcentrateinjectionsforsymptomatickneeosteoarthritis
AT robinsonryan functionaloutcomesfollowingmicrofragmentedadiposetissueversusbonemarrowaspirateconcentrateinjectionsforsymptomatickneeosteoarthritis